• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,202.15
  • 0.65 %
  • $52.88
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Denali Therapeutics Inc. (DNLI) Stock Price, News & Analysis

Denali Therapeutics Inc. (DNLI) Stock Price, News & Analysis

Currency in USD Disclaimer

$24.23

-$0.19

(-0.78%)

Day's range
$23.8
Day's range
$24.79
50-day range
$23.53
Day's range
$33.33
  • Country: US
  • ISIN: US24823R1059
52 wk range
$14.56
Day's range
$33.33
  • CEO: Dr. Ryan J. Watts Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 13.35
  • Piotroski Score 2.00
  • Grade Buy
  • Symbol (DNLI)
  • Company Denali Therapeutics Inc.
  • Price $24.23
  • Changes Percentage (-0.78%)
  • Change -$0.19
  • Day Low $23.80
  • Day High $24.79
  • Year High $33.33

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/25/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $35.00
  • High Stock Price Target $70.00
  • Low Stock Price Target $22.00
  • Potential Upside/Downside N/A
  • Consensus Rating Strong Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.94
  • Trailing P/E Ratio -22.1
  • Forward P/E Ratio -22.1
  • P/E Growth -22.1
  • Net Income $-145,224,000

Income Statement

Quarterly

Annual

Latest News of DNLI

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Denali Therapeutics Inc. Frequently Asked Questions

  • What is the Denali Therapeutics Inc. stock price today?

    Today's price of Denali Therapeutics Inc. is $24.23 — it has decreased by -0.78% in the past 24 hours. Watch Denali Therapeutics Inc. stock price performance more closely on the chart.

  • Does Denali Therapeutics Inc. release reports?

    Yes, you can track Denali Therapeutics Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Denali Therapeutics Inc. stock forecast?

    Watch the Denali Therapeutics Inc. chart and read a more detailed Denali Therapeutics Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Denali Therapeutics Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Denali Therapeutics Inc. stock ticker.

  • How to buy Denali Therapeutics Inc. stocks?

    Like other stocks, DNLI shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Denali Therapeutics Inc.'s EBITDA?

    Denali Therapeutics Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Denali Therapeutics Inc.’s financial statements.

  • What is the Denali Therapeutics Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.4393657478, which equates to approximately -43.94%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Denali Therapeutics Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Denali Therapeutics Inc.'s financials relevant news, and technical analysis. Denali Therapeutics Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Denali Therapeutics Inc. stock currently indicates a “sell” signal. For more insights, review Denali Therapeutics Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.